Literature DB >> 29563539

An NF90/NF110-mediated feedback amplification loop regulates dicer expression and controls ovarian carcinoma progression.

Jérôme Barbier1, Xin Chen1,2, Gabriel Sanchez1, Muyan Cai2, Marion Helsmoortel1, Takuma Higuchi3, Pierre Giraud1, Xavier Contreras1, Gangjun Yuan2, Zihao Feng4, Rima Nait-Saidi1, Olivier Deas5, Lisa Bluy1, Jean-Gabriel Judde5, Sylvie Rouquier1, William Ritchie6, Shuji Sakamoto3, Dan Xie7, Rosemary Kiernan8.   

Abstract

Reduced expression of DICER, a key enzyme in the miRNA pathway, is frequently associated with aggressive, invasive disease, and poor survival in various malignancies. Regulation of DICER expression is, however, poorly understood. Here, we show that NF90/NF110 facilitates DICER expression by controlling the processing of a miRNA, miR-3173, which is embedded in DICER pre-mRNA. As miR-3173 in turn targets NF90, a feedback amplification loop controlling DICER expression is established. In a nude mouse model, NF90 overexpression reduced proliferation of ovarian cancer cells and significantly reduced tumor size and metastasis, whereas overexpression of miR-3173 dramatically increased metastasis in an NF90- and DICER-dependent manner. Clinically, low NF90 expression and high miR-3173-3p expression were found to be independent prognostic markers of poor survival in a cohort of ovarian carcinoma patients. These findings suggest that, by facilitating DICER expression, NF90 can act as a suppressor of ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29563539      PMCID: PMC5951825          DOI: 10.1038/s41422-018-0016-8

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  57 in total

1.  Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans.

Authors:  R F Ketting; S E Fischer; E Bernstein; T Sijen; G J Hannon; R H Plasterk
Journal:  Genes Dev       Date:  2001-10-15       Impact factor: 11.361

2.  Reduced expression of Dicer associated with poor prognosis in lung cancer patients.

Authors:  Yoko Karube; Hisaaki Tanaka; Hirotaka Osada; Shuta Tomida; Yoshio Tatematsu; Kiyoshi Yanagisawa; Yasushi Yatabe; Junichi Takamizawa; Shinichiro Miyoshi; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Sci       Date:  2005-02       Impact factor: 6.716

3.  DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function.

Authors:  Reed S Shabman; Daisy W Leung; Joshua Johnson; Nicole Glennon; Erol E Gulcicek; Kathryn L Stone; Lawrence Leung; Lisa Hensley; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

4.  Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing.

Authors:  A Grishok; A E Pasquinelli; D Conte; N Li; S Parrish; I Ha; D L Baillie; A Fire; G Ruvkun; C C Mello
Journal:  Cell       Date:  2001-07-13       Impact factor: 41.582

5.  A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells.

Authors:  Sonia A Melo; Catia Moutinho; Santiago Ropero; George A Calin; Simona Rossi; Riccardo Spizzo; Agustin F Fernandez; Veronica Davalos; Alberto Villanueva; Guillermo Montoya; Hiroyuki Yamamoto; Simo Schwartz; Manel Esteller
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

Review 6.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

7.  The nuclear RNase III Drosha initiates microRNA processing.

Authors:  Yoontae Lee; Chiyoung Ahn; Jinju Han; Hyounjeong Choi; Jaekwang Kim; Jeongbin Yim; Junho Lee; Patrick Provost; Olof Rådmark; Sunyoung Kim; V Narry Kim
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

8.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

9.  Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B.

Authors:  X-D Li; J-X Zhang; L-J Jiang; F-W Wang; L-L Liu; Y-J Liao; X-H Jin; W-H Chen; X Chen; S-J Guo; F-J Zhou; Y-X Zeng; X-Y Guan; Z-W Liu; D Xie
Journal:  Oncogene       Date:  2016-05-16       Impact factor: 9.867

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  12 in total

1.  NF90 stabilizes cyclin E1 mRNA through phosphorylation of NF90-Ser382 by CDK2.

Authors:  Donglin Ding; Huixing Huang; Quanfu Li; Wenbo Yu; Chenji Wang; Haijie Ma; Jiaxue Wu; Yongjun Dang; Long Yu; Wei Jiang
Journal:  Cell Death Discov       Date:  2020-01-22

2.  LINC00893 inhibits the progression of prostate cancer through miR-3173-5p/SOCS3/JAK2/STAT3 pathway.

Authors:  Chuigong Yu; Yu Fan; Yu Zhang; Lupeng Liu; Gang Guo
Journal:  Cancer Cell Int       Date:  2022-07-10       Impact factor: 6.429

3.  circACTA2 mediates Ang II-induced VSMC senescence by modulation of the interaction of ILF3 with CDK4 mRNA.

Authors:  Ying Ma; Bin Zheng; Xin-Hua Zhang; Zi-Yuan Nie; Jing Yu; Hong Zhang; Dan-Dan Wang; Bei Shi; Yang Bai; Zhan Yang; Jin-Kun Wen
Journal:  Aging (Albany NY)       Date:  2021-04-22       Impact factor: 5.682

4.  Biocompatible supramolecular pseudorotaxane hydrogels for controllable release of doxorubicin in ovarian cancer SKOV-3 cells.

Authors:  Caixia Li; Hanxue Li; Jiahao Guo; Liang Li; Xiaowei Xi; Yanyan Yu
Journal:  RSC Adv       Date:  2020-01-02       Impact factor: 4.036

5.  The positive feedback loop between ILF3 and lncRNA ILF3-AS1 promotes melanoma proliferation, migration, and invasion.

Authors:  Guozhen Gao; Wenjun Li; Sha Liu; Dongmei Han; Xingwei Yao; Juanjuan Jin; Dezhi Han; Weijing Sun; Xiangjun Chen
Journal:  Cancer Manag Res       Date:  2018-12-11       Impact factor: 3.989

6.  An NF90/long noncoding RNA-LET/miR-548k feedback amplification loop controls esophageal squamous cell carcinoma progression.

Authors:  Jianqing Lin; Zhiyao Chen; Shanhu Wu; Wenbo Huang; Feng Chen; Zhijun Huang
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

7.  NF90 stabilizes cyclin E1 mRNA through phosphorylation of NF90-Ser382 by CDK2.

Authors:  Donglin Ding; Huixing Huang; Quanfu Li; Wenbo Yu; Chenji Wang; Haijie Ma; Jiaxue Wu; Yongjun Dang; Long Yu; Wei Jiang
Journal:  Cell Death Discov       Date:  2020-01-22

8.  Regulated dicing of pre-mir-144 via reshaping of its terminal loop.

Authors:  Renfu Shang; Dmitry A Kretov; Scott I Adamson; Thomas Treiber; Nora Treiber; Jeffrey Vedanayagam; Jeffrey H Chuang; Gunter Meister; Daniel Cifuentes; Eric C Lai
Journal:  Nucleic Acids Res       Date:  2022-07-22       Impact factor: 19.160

9.  An integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancer.

Authors:  Pouria Samadi; Meysam Soleimani; Fatemeh Nouri; Fatemeh Rahbarizadeh; Rezvan Najafi; Akram Jalali
Journal:  BMC Cancer       Date:  2022-07-30       Impact factor: 4.638

10.  Upregulated long non‑coding RNA LincIN promotes tumor progression via the regulation of nuclear factor 90/microRNA‑7/HOXB13 in esophageal squamous cell carcinoma.

Authors:  Zhibo Tan; Peitao Zhou; Zhenru Zhu; Ying Wang; Zeqin Guo; Mengying Shen; Yazhi Xiao; Weixi Shen; Dehua Wu
Journal:  Int J Mol Med       Date:  2021-03-11       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.